Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts

Targeting CD33 or CD45 is currently exploited for immunotherapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO), an immunoconjugate of an anti-CD33 antibody that facilitates cellular uptake of a toxic calicheamicin-γ(1) derivative, induces complete remissions in a subset of patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Walter, Roland B., Boyle, Kelli M., Appelbaum, Frederick R., Bernstein, Irwin D., Pagel, John M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2008
Aiheet:
Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2343609/
https://ncbi.nlm.nih.gov/pubmed/18326813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-01-133785
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia